Export Potential of the Russian Pharmaceutical Market and its Prospects

  • Abstract
  • Keywords
  • References
  • PDF
  • Abstract

    Export of medicines is one of the most profitable businesses, which attracts the attention of an increasing number of producers. The international medicines’ trade largely depends on national or regional regulatory mechanisms. In addition, the export terms and conditions differ for various categories of medicines. Innovative drugs account for the main share of the global medicines’ export. Therefore, export of innovative drugs developed in Russia to advanced countries is the most economically profitable direction. Export of generic drugs can bring considerable revenue to the producer and the state, but import substitution by releasing generic drugs weakens the innovative direction of studies and production. The import substitution policy targets manufacturers of medicines to produce generic drugs, as well as products intended, mainly or exclusively, for sale within the country. One of the ways to improve the efficiency of the entire pharmaceutical sector is international cooperation.



  • Keywords

    export of medicines, import substitution strategy for drugs, development of pharmaceutical and medical industry, medicines, active pharmaceutical ingredients (APIs).

  • References

      [1] Decree of the Government of the Russian Federation of December 28, 2017 No. 1673 “On amendments to the State Program of the Russian Federation Development of pharmaceutical and medical industry for 2013-2020”.

      [2] United Nations. Resolution adopted by the General Assembly on
      25 September 2015. Transforming our world: the 2030 Agenda
      for Sustainable Development. A/RES/70/1. http://docs.cntd.ru/

      [3] International trade in medicinal and pharmaceutical products. Eurostat. Statistics explained. May 2017. http://ec.europa.eu/

      [4] Addressing the global shortage of, and access to, medicines and vaccines. Report by the Director-General. WHO, Executive Board, 142nd session. EB142/13, 12 January 2018. http://apps.who.int/gb/ebwha/pdf_files/EB142/B142_13-en.pdf.

      [5] Meshkovsky A. P., Pyatigorskaya N. V., Aladysheva Zh. I., Ivashechkova N. S., Shabalina M. M. (2017) Farmatsevticheskaya promyshlennost’ Indii [Pharmaceutical industry of India] // Remedium, No. 5. pp. 6-10.

      [6] Global Antibiotic Research & Development Partnership (https://www.gardp.org/) EB142/14.

      [7] Global Observatory on Health Research and Development. (http://www.who.int/research-observatory/en).

      [8] Development of paediatric medicines: points to consider in formulation. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-sixth report. Geneva, World Health Organization, 2012, Annex 5. WHO Technical Report Series, No. 970.

      [9] Guidelines for registration of fixed-dose combination medicinal products. Appendix 3: Pharmaceutical development (or preformulation) studies. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth report. Geneva, World Health Organization, 2005, Annex 5. WHO Technical Report Series, No. 929.

      [10] Guidelines on submission of documentation for a multisource (generic) finished pharmaceutical product: quality part. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report. Geneva, World Health Organization, 2014, Annex 6. WHO Technical Report Series, No. 986.

      [11] 67-aya sessiya Vsemirnoi assamblei zdravookhraneniya. Ukreplenie normativnoi sistemy dlya meditsinskoi produktsii. [67th session of the World Health Assembly. (2014) Regulatory System Strengthening for Medical Products]. WHA67.20. http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_R20-ru.pdf.




Article ID: 27766
DOI: 10.14419/ijet.v7i4.38.27766

Copyright © 2012-2015 Science Publishing Corporation Inc. All rights reserved.